Vedolizumab

Study	Exclusion reasons	Rmk	Reference
Bar-Gil, 2019	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: This is a subset of the study population published in Moens et al. 2020.	Bar-Gil Shitrit Am. J. Gastroenterol. 2019; 114:1172-1175 10.14309/ajg.0000000000000186
Moens, 2019	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: This is a subset of the study population published in Moens et al. 2020.	Moens J Crohns Colitis 2019; 13:12-18 10.1093/ecco-jcc/jjy142
Julsgaard, 2017	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: This is a subset of the study population published in Moens et al. 2020.	Julsgaard Gut 2017; 66:1866-1867 10.1136/gutjnl-2016-313444
Beaulieu, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analyses performed for the group of pregnancies exposed to biologic exposed patients, without analysis for each substance : 27 were on infliximab, 7 on adalimumab, 3 on certolizumab, 2 each on natalizumab and ustekinumab, and 1 on vedolizumab.	Beaulieu DB Clin Gastroenterol Hepatol 2018;16:99-105 10.1016/j.cgh.2017.08.041
Koslowsky, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: no distinction between treatments.	Koslowsky Inflamm. Bowel Dis. 2018; 24:1826-1832 10.1093/ibd/izy081